Project no.: HIV-NAT 128
A randomized, double-blind, placebo-controlled, clinical trial to compare the safety and efficacy of reduced dose (400mg) efavirenz (EFV) with standard dose EFV plus two nucleotide reverse transcriptase inhibitors (N(t)RTI) in antiretroviral-naive HIV-infected individuals over 96 weeks. HIV-NAT is the Thai co-ordinating centre. There are three substudies: 1) CNS, 2) Intensive PK and 3) Neurocognitive substudy. Staff from HIV-NAT have initiated this last substudy and will be responsible for the data collection and sub-study analysis.
Publications:
- J Antimicrobial Ther 2011; 66: 635‐40
- Lancet. 2014;383(9927):1474-82.
